R1	Subsumes Arg1:T1 Arg2:T2	
*	OR T3 T4
R2	Subsumes Arg1:T6 Arg2:T8	
R3	Subsumes Arg1:T7 Arg2:T9	
*	OR T6 T7 T10
R4	AND Arg1:T4 Arg2:T6	
R5	Has_value Arg1:T6 Arg2:T5	
R6	Has_temporal Arg1:T14 Arg2:T13	
R7	Has_multiplier Arg1:T15 Arg2:T16	
R8	Has_qualifier Arg1:T18 Arg2:T15	
R9	Subsumes Arg1:T18 Arg2:T19	
*	OR T20 T21 T22
R10	AND Arg1:T23 Arg2:T20	
R11	Has_temporal Arg1:T20 Arg2:T24	
R12	Has_negation Arg1:T30 Arg2:T28	
R13	Has_qualifier Arg1:T26 Arg2:T27	
R14	Has_temporal Arg1:T26 Arg2:T29	
R15	Has_negation Arg1:T32 Arg2:T31	
R16	Has_qualifier Arg1:T36 Arg2:T37	
*	OR T36 T39
*	OR T34 T35
R17	Subsumes Arg1:T36 Arg2:T38	
R18	Subsumes Arg1:T34 Arg2:T36	
R19	Has_temporal Arg1:T42 Arg2:T43	
R20	AND Arg1:T45 Arg2:T46	
R21	Has_index Arg1:T44 Arg2:T45	
*	OR T47 T48
R22	Has_qualifier Arg1:T50 Arg2:T49	
R23	Has_temporal Arg1:T53 Arg2:T52	
R24	AND Arg1:T50 Arg2:T53	
R25	Has_temporal Arg1:T47 Arg2:T44	
R26	AND Arg1:T47 Arg2:T51	
*	OR T47 T50
R27	Has_temporal Arg1:T34 Arg2:T55	
R28	Has_temporal Arg1:T26 Arg2:T56	
R29	Has_temporal Arg1:T58 Arg2:T57	
R30	AND Arg1:T58 Arg2:T59	
R31	Has_value Arg1:T61 Arg2:T60	
R32	multi Arg1:T62 Arg2:T61	
R33	Has_value Arg1:T65 Arg2:T60	
R34	Has_value Arg1:T66 Arg2:T60	
R35	multi Arg1:T63 Arg2:T65	
R36	multi Arg1:T64 Arg2:T66	
*	OR T62 T63 T64
*	OR T67 T68
R37	Has_qualifier Arg1:T72 Arg2:T71	
R38	AND Arg1:T70 Arg2:T72	
*	OR T74 T75
R40	Has_context Arg1:T77 Arg2:T78	
R41	Has_context Arg1:T81 Arg2:T78	
*	OR T77 T81
T1	Condition 0 18;32 37	Metastatic disease NSCLC
T2	Condition 19 31	(M1)/stage 4
T3	Condition 39 46;62 70	Pleural effusion
T4	Condition 50 70	pericardial effusion
T5	Value 71 100	greater than 100 ml in volume
T6	Measurement 139 167	positron emission tomography
T7	Measurement 175 194;200 204	computed tomography scan
T8	Measurement 169 172	PET
T9	Measurement 196 198	CT
T10	Measurement 208 218	ultrasound
T12	Non-query-able 39 744	Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging (positron emission tomography [PET], computed tomography [CT] scan or ultrasound). If an effusion greater than 100 ml is documented by cytology to be free from malignancy and the investigator feels the patient is capable of receiving chemo/radiotherapy for their primary disease/ NSCLC, the investigator should discuss the patient with the study physician at Amgen. Effusions smaller than 100 ml would be acceptable, unless the investigator suspects that the effusion is malignant, in which case the effusions should be evaluated by cytology. Sponsor approval must be obtained before patient is randomized.
T13	Temporal 782 838	before completing the protocol chemo/radiotherapy course
T14	Mood 746 781	Plan to remove the tumor surgically
T15	Qualifier 869 878	esophagus
T16	Multiplier 853 864	any part of
T17	Procedure 886 898	radiotherapy
T18	Procedure 840 849	Shielding
T19	Procedure 910 941	posterior spinal cord shielding
T20	Drug 950 962	chemotherapy
T21	Procedure 964 976	radiotherapy
T22	Procedure 981 988	surgery
T23	Condition 993 998	NSCLC
T24	Temporal 944 949	Prior
T26	Condition 1015 1025	malignancy
T27	Qualifier 1006 1014	invasive
T29	Temporal 1026 1049	during the past 3 years
T28	Negation 1050 1060	other than
T30	Condition 1061 1089	non-melanomatous skin cancer
T31	Negation 1232 1239	are not
T32	Condition 1117 1146	surgically-cured malignancies
T33	Non-query-able 1259 1321	sponsor approval must be obtained before patient is randomized
T34	Condition 1347 1356	dysphagia
T35	Condition 1360 1396	conditions predisposing to dysphagia
T36	Condition 1415 1446	gastroesophageal reflux disease
T37	Qualifier 1402 1414	uncontrolled
T38	Condition 1448 1452	GERD
T39	Condition 1455 1464	dyspepsia
T42	Condition 1483 1495	pancreatitis
T43	Temporal 1472 1482	History of
T44	Temporal 1497 1545	Four weeks or less since completion of treatment
T45	Reference_point 1522 1545	completion of treatment
T46	Procedure 1536 1545	treatment
T47	Drug 1555 1578	investigational product
T48	Device 1555 1570;1579 1585	investigational device
T49	Qualifier 1631 1641	unresolved
T50	Condition 1642 1650	toxicity
T51	Competing_trial 1589 1611	another clinical study
T52	Temporal 1656 1664	previous
T53	Procedure 1665 1674	treatment
T55	Temporal 1336 1346	history of
T56	Temporal 1000 1005	Prior
T57	Temporal 1676 1684	Previous
T58	Procedure 1685 1694	treatment
T59	Drug 1719 1743	fibroblast growth factor
T60	Value 1757 1770	sero-positive
T61	Measurement 1775 1809	human immunodeficiency virus (HIV)
T62	Condition 1757 1809	sero-positive for human immunodeficiency virus (HIV)
T63	Condition 1757 1774;1811 1834	sero-positive for hepatitis C virus (HCV)
T64	Condition 1757 1774;1839 1862	sero-positive for hepatitis B virus (HBV)
T65	Measurement 1811 1834	hepatitis C virus (HCV)
T66	Measurement 1839 1862	hepatitis B virus (HBV)
T67	Condition 1864 1872	Pregnant
T68	Condition 1876 1889	breastfeeding
T69	Person 1890 1895	women
T70	Condition 1903 1914	sensitivity
T71	Qualifier 1918 1933	E. coli derived
T72	Drug 1934 1942	products
T73	Condition 1944 1963	Compromised ability
T74	Informed_consent 1982 2011	give written informed consent
T75	Non-representable 2022 2050	comply with study procedures
T77	Informed_consent 2063 2092	sign an informed consent form
T78	Observation 2052 2062	Refusal to
T79	Non-representable 2186 2267	Unwilling or unable to complete the patient reported outcome (PRO) questionnaires
T80	Non-query-able 2269 2362	Psychological, social, familial, or geographical reasons that would prevent regular follow-up
T81	Informed_consent 2127 2169	sign the hospital information release form
